Q-omics provides the consensus-scored PRAMEF18 profile across patient tissues and cancer cell-line models. PRAMEF18 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRAMEF18 is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, PRAMEF18 RNA expression shows 8,274 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, BRCA, and TGCT as cancer lineages where PRAMEF18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF18 survival associations across molecular data types. PRAMEF18 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF18 RNA expression–survival associations across cancer types. High PRAMEF18 expression shows unfavorable associations in KIRC, UCS, MESO, SKCM, BRCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRAMEF18 RNA expression.
This table summarizes PRAMEF18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for PRAMEF18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRAMEF18 shows lower tumor expression in BRCA. The BRCA box plot shows higher PRAMEF18 RNA expression in normal versus tumor tissue (log2 FC = −0.006, t-test p = .028).
This table shows molecular features associated with PRAMEF18 in patient tissues and cancer cell lines. In patient samples, PRAMEF18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
